Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Austedo xr choreahd medication costts?Opdualag patent expiration date?Novartis eltrombopag tablets?Revolade eltrombopag us market launch date?Canadian patent expiry for dalbavancin?
See the DrugPatentWatch profile for Exparel
Current State of Exparel's Market Share Exparel (bupivacaine liposome) is a local anesthetic used to manage postoperative pain in adults. In 2018, it was the subject of a patent-related controversy. [1] Impact of Patent Challenging on Market Share Several companies have challenged the Exparel patent, particularly the one held by the pharmaceutical company PainSpring LLC. This has opened up the market for generic versions of the drug, which could potentially decrease Exparel's market share. [2] Competitive Landscape Other medications, such as Ionsys (fentanyl iontophoretic transdermal system), have been developed to compete in this market. While Ionsys has its own patent issues, it offers an alternative solution for pain management. [3] Patent Expiration Timeline The exclusivity period for Exparel was set to expire in 2038, but the patent challenges have brought the timeline forward. The exact date for the patent to expire cannot be determined until the litigation process concludes. [4] Future Outlook The entry of generic or biosimilar competitors could significantly impact Exparel's market share. However, the patent expiration timeline provides some insight into the market's future direction. Sources: [1] DrugPatentWatch.com [2] Statista News [3] Investopedia [4] Patent Watch The information provided is based on publicly available sources and might not reflect the current market situation.
Other Questions About Exparel :